Approximately 20% to 25% of breast cancer cases exhibit HER2 overexpression, which is characterized by a higher propensity to display metastasis, resistance to chemotherapy and hormonal therapy, shortened survival, and poor prognosis. The gene discussed is ERBB2; the disease is breast carcinoma.